News Updates
More Articles
- Benefits of Integrating Patient Engagement with Diversity, Equity, and Inclusion in New Medical Product Development: A Call for Action
- Drug Shortages in the Global South: A Proposed Parallel Tech and Reg Transfer Framework
- Fair Pay for Patient Engagement: Navigating the Evolving Landscape of Remuneration
- Industry’s Window to Express Interest in Africa Continental Product Evaluation Pilot Closes End of February 2024
- The Importance of Regulatory Due Diligence During the Acquisition Process
DIA China 2021: China GVP: Lifecycle Pharmacovigilance and Patient Safety
In May 2021, the NMPA in China issued an announcement about Good Pharmacovigilance Practice, hereafter referred to as GVP, the first pharmacovigilance guideline issued in accordance with China’s new Drug Administration Law of the People’s Republic of China, the first time the term “pharmacovigilance” is officially reflected in the Drug Administration Law of China.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!